⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

Regeneron made no additions or removals to its risk factor categories between the 2024 and 2025 10-K filings, maintaining 55 unchanged risks while substantively modifying 5 existing risk disclosures. The most significant modifications involved heightened language around manufacturing regulatory compliance requirements and increased emphasis on dependence risks for key commercial products EYLEA, EYLEA HD, and Dupixent. These changes reflect updated risk articulation rather than fundamental shifts in Regeneron's disclosed risk profile.

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

🟡 Modified Our or our collaborators' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales. 🔒

🟡 Modified We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent. 🔒

🟡 Modified If we are unable to establish sufficient commercial capabilities outside the United States for products we intend to commercialize or co-commercialize outside the United States, our business, prospects, operating results, and financial condition may be adversely affected. 🔒

🟡 Modified We face risks related to the personal data we collect, process, and share. 🔒

🟡 Modified There can be no assurance that we will continue to repurchase shares of our Common Stock or continue to declare cash dividends. 🔒

5 changes in this historical filing

Historical year-over-year comparisons (2025 vs 2024 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →